Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Launch engagement

How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement

- PMLiVE

Mastering commercial launch excellence in a human-centric, hybrid world

By Mike Ballas, Madelaine Allen and Dan Masquelier

- PMLiVE

FDA approves Apellis’ Empaveli for rare blood disease

PEGASUS study results show Empaveli is better than Soliris at improving haemoglobin levels

- PMLiVE

BMS builds case for cardiovascular drug mavacamten with new analysis

BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

Avenir Global moves four UK agencies into new office space in London

AXON, Cherry, Hanover and Madano will now be based in London’s Bankside area

- PMLiVE

WebMD acquires UK-based healthcare publisher MGP

MGP will continue to operate as an independent subsidiary following acquisition completion

Research Partnership’s MedTech Division appoints two Directors

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Inizio

- PMLiVE

VMLY&Rx launches new payer agency in the US

VMLY&Rx Payer will be helmed by healthcare comms industry veteran HeeSun Yu

Biogen Idec building

Biogen and Envisagenics to advance RNA splicing research for CNS diseases

Envisagenics’ SpliceCore platform can be used to identify, test and validate RNA splicing errors at scale

- PMLiVE

Your brand experience matters

By Simon Hackett

- PMLiVE

NICE recommends Keytruda for colorectal cancer patients with rare mutations

Approximately 450 patients in England will now become eligible for this treatment on the NHS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links